These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 6878352)

  • 1. Safety evaluation of hemoglobin solutions.
    Fratantoni JC
    Prog Clin Biol Res; 1983; 122():111-5. PubMed ID: 6878352
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes in the peripheral blood, liver and spleen during the long-term experimental administration of modified hemoglobin].
    Selivanov EA; Shabalin VN; Bystrova IM; Molokovskaia IE; Rugal' VI
    Biull Eksp Biol Med; 1989 Apr; 107(4):488-90. PubMed ID: 2720169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety studies of modified hemoglobin as an oxygen-carrying blood substitute.
    Chang TM
    Hematol Pathol; 1993; 7(1):49-55. PubMed ID: 8468266
    [No Abstract]   [Full Text] [Related]  

  • 4. Toxicity of polymerized hemoglobin solutions.
    Feola M; Simoni J; Canizaro PC; Tran R; Raschbaum G; Behal FJ
    Surg Gynecol Obstet; 1988 Mar; 166(3):211-22. PubMed ID: 3344450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities of hemoglobin solutions: in search of in-vitro and in-vivo model systems.
    Buehler PW; Alayash AI
    Transfusion; 2004 Oct; 44(10):1516-30. PubMed ID: 15383027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating new red cell substitutes: a critical analysis of toxicity models.
    Greenburg AG; Kim HW
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):575-9. PubMed ID: 1391480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology and ultrastructure of liver and kidney following blood exchange with ultrapurified, polymerised bovine hemoglobin in comparison with hydroxyethyl starch.
    Lipfert B; Standl T; Düllmann J; Helmchen U; Schulte am Esch J; Lorke DE
    Lab Invest; 1999 May; 79(5):573-82. PubMed ID: 10334568
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of o-raffinose-polymerized human hemoglobin on coronary tone and cardiac function in isolated hearts.
    Vogel WM; Cassidy G; Valeri CR
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):673-7. PubMed ID: 1391494
    [No Abstract]   [Full Text] [Related]  

  • 9. An improved blood substitute. In vivo evaluation of its renal effects.
    Simoni J; Simoni G; Hartsell A; Feola M
    ASAIO J; 1997; 43(5):M714-25. PubMed ID: 9360140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Use of stroma-free hemoglobin solutions as blood substitute].
    Birkigt HG; Heinrich P; Brandstädter W; Fritzsche L
    Z Exp Chir; 1980; 13(4):230-4. PubMed ID: 7415348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineering and design of blood substitutes.
    Sanders KE; Ackers G; Sligar S
    Curr Opin Struct Biol; 1996 Aug; 6(4):534-40. PubMed ID: 8794165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preclinical screening test for modified hemoglobin to bridge the gap between animal safety studies and use in human.
    Chang TM; Lister C
    Biomater Artif Cells Immobilization Biotechnol; 1992; 20(2-4):565-73. PubMed ID: 1391479
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig.
    Buehler PW; D'Agnillo F; Hoffman V; Alayash AI
    J Pharmacol Exp Ther; 2007 Oct; 323(1):49-60. PubMed ID: 17622572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Changes in the structure of lymphoid organs in the post-shock period after blood loss replacement with hemoglobin-containing solutions].
    Timchenko AS
    Vrach Delo; 1983 Oct; (10):43-6. PubMed ID: 6359695
    [No Abstract]   [Full Text] [Related]  

  • 15. The physiologic effects of oxygen transport by hemoglobin solutions.
    Moores WY; White FC; Bloor C; Greenburg AG; Mack R; Willford DC
    Prog Clin Biol Res; 1983; 122():89-99. PubMed ID: 6878384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of toxicity of hemoglobin solutions.
    Feola M; Simoni J; Tran R; Canizaro PC
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):217-26. PubMed ID: 3179466
    [No Abstract]   [Full Text] [Related]  

  • 17. Immunological and systemic effects of transfusions in rats using pyridoxylated hemoglobin and polyhemoglobin from homologous and heterogeneous sources.
    Chang TM; Varma R
    Biomater Artif Cells Artif Organs; 1988; 16(1-3):205-15. PubMed ID: 3179465
    [No Abstract]   [Full Text] [Related]  

  • 18. [Artificial blood--the past, present, and future (II)].
    Minoshima T
    Kokyu To Junkan; 1982 Oct; 30(10):970-9. PubMed ID: 6760310
    [No Abstract]   [Full Text] [Related]  

  • 19. Points to consider in the safety evaluation of hemoglobin-based oxygen carriers. Center for Biologics Evaluation and Research.
    Transfusion; 1991 May; 31(4):369-71. PubMed ID: 2021002
    [No Abstract]   [Full Text] [Related]  

  • 20. The development of hemoglobin solutions as red cell substitutes.
    Ogden JE; Parry ES
    Int Anesthesiol Clin; 1995; 33(1):115-29. PubMed ID: 7635553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.